4 results about "Sertraline" patented technology

The invention discloses a nicardipine delivery system and application of the nicardipine delivery system in resisting post-traumatic stress disorder. According to the present invention, the functional modification is performed on the PLGA-PEG to develop the brain enrichment type PLGA-PEG-MANNOse molecule, the nicardipine is subjected to nanometer modification, the blood brain barrier permeability is enhanced, and the fear memory disorder of the post-traumatic stress disorder model animal can be effectively relieved; research finds that when PPM-N is used for treating mice related to electric shock complicated post-traumatic stress disorder, indexes of multiple experimental results are equivalent to serotonin reuptake inhibitor medicine sertraline. Related experiments show that PPM-N has the effect of treating and / or relieving post-traumatic stress disorder and has a good clinical application prospect.

The application discloses a method for simultaneously detecting the concentration of six drugs in blood, comprising the following steps: S1, taking a blood sample, centrifuging, and adding methanol to precipitate protein; S2, preparing a series of concentration calibration solution, quality control sample and internal standard working solution; S3, adding the internal standard working solution to the supernatant 1 prepared in S1, vortex mixing, centrifuging, and taking the supernatant 2; S4, using high performance liquid chromatography-tandem mass spectrometry to detect the supernatant 2 obtained in S3 for the selected drugs, and performing mass spectrometry screening analysis on the basis of the retention time of the compound, two pairs or three pairs of parent ions / daughter ions; the drugs include one, multiple or all of fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram and escitalopram; the detection method provided by the application has the characteristics of simple and convenient sample pretreatment, small required sample volume, high sensitivity, high accuracy and high throughput.

The invention discloses an application of ergomine in preparation of a medicine for treating post-traumatic stress disorder caused by electric shock. According to the method, a post-traumatic stress disorder model is firstly constructed, and the result shows that in post-traumatic stress disorder model animals, remarkable core behavior characteristics such as fear overconsolidation memory and the like are shown. The ergotramine is used for intervention treatment, so that the fear memory fading capability of the model animal is obviously improved; behavior experiment comprehensive evaluation shows that the stiffness time of animals in an ergotramine treatment group is remarkably shortened. Experimental results show that the ergotramine can effectively relieve fear memory disorder of post-traumatic stress disorder model animals. Research finds that when the ergotramine is used for treating mice related to the electric shock complicated post-traumatic stress disorder, the index of an experimental result is superior to that of serotonin reuptake inhibitor medicine sertraline. Related experiments show that the ergotramine has the effect of treating and / or relieving post-traumatic stress disorder and has a good clinical application prospect.

The present disclosure provides a method of treating or reducing a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising sertraline and a crystalline form of psilocybin, wherein the crystalline form is co-crystal Form A of sertraline and psilocybin. The present disclosure further provides a method of stimulating induced neural plasticity, increasing BDNF levels, and / or reducing neuroinflammation.